x

RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

United States ( XML Feed )

Oct 5, 2016 10:02 EST

Kineta, Inc rapidly advances leading-edge immunotherapeutic drug candidates through human safety trials, transacts with Pharma, 3 yr. est. to ROI

iCrowdNewswire - Oct 5, 2016

2 20color 20kineta 20logo 20  20new 20tagline

Kineta, Inc.

Kineta rapidly advances leading-edge immunotherapeutic drug candidates through human safety trials, transacts with Pharma, 3 yr. est. to ROI

Good 20light 20  20group jpg

Company Summary

 

Kineta is a biotech company that fills a void in the pharma industry by advancing therapies from discovery to clinical proof of concept. We work with private, government and industry partners to advance our innovative research. Our unique funding model mitigates risk and may provide an attractive and earlier return for investors. Kineta has established and a pipeline of novel life improving therapies that address critical unmet patient needs.

 
  • StageProduct In Development
  • IndustryBiotechnology
  • LocationSeattle, WA, USA
  • CurrencyUSD
  • FoundedDecember 2007
  • Employees39
  • Incorporation TypeC-corp
  • Websitekinetabio.com

Team

  • Default avatar
    Shawn Iadonato, PhD
    CEO and Chief Science Officer
    Unconfirmed

    Dr. Iadonato previously co-founded and was CSO of Illumigen Biosciences Inc. where he pioneered the company’s patented drug discovery methodology driven by recruitment and screening of healthy populations. He also led the successful discovery and preclinical development of Illumigen’s anti-HCV drug IB657, which ultimately led to the sale of the company. Earlier he managed the Human Genome Project data collection at the U.W. Genome Center.

     

     

  • Default avatar
    Rob Hedequist
    President and COO
    Unconfirmed

    20+ years in the pharmaceutical industry; Corporate development at Kineta; Major Accounts, Managed Care & Sales/ Marketing at Pfizer and Amgen; National Director Schering–Plough

Contact Information:

Shawn Iadonato

View Related News >
support